TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05932641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD3152 (Cohort 1)
Description: Single dose of AZD3152 300 mg IM on Visit 2 Day 1

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Cohort 1)
Description: Single dose of Placebo IM on Visit 2 Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD3152 (Cohort 2)
Description: Single dose of AZD3152 600 mg IM on Visit 2 Day 1

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Cohort 2)
Description: Single dose of Placebo IM on Visit 2 Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD3152 (Cohort 3)
Description: Single dose of AZD3152 1200 mg IV on Visit 2 Day 1

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Cohort 3)
Description: Single dose of Placebo IM on Visit 2 Day 1
Study: NCT05690581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM369
Description: Specified dose on specified days.
Study: NCT03806751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [O-15]Water
Description: All study participants with undergo brain imaging with \[O-15\]water-PET/MRI without and with administration of the carbonic anhydrase inhibitor acetazolamide. The PET tracer will be used to measure regional cerebral perfusion, and the administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
Study: NCT05631327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP341
Description: JZP341 will be administered as a single, intravenous infusion over 2 hours.
Study: NCT03806751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: The administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
Study: NCT05927727

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound and biyopsy
Description: Each participant has undergone to ultrasound and biopsy procedure if they have suspicious lymph node in axillar region

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound and biyopsy
Description: Each participant has undergone to ultrasound and biopsy procedure if they have suspicious lymph node in axillar region
Study: NCT06121557

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery for harvesting tumor-draining lymph nodes
Description: A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 500 mg/m\^2 IV daily for three days. Cyclophosphamide will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered at 30 mg/m\^2 IV daily for three days. Fludarabine will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-draining lymph node-derived lymphocyte (LNL)
Description: In the dose-escalation portion, participants receive ascending dose (1×10\^9\~18×10\^9), single Infusion of LNL on day 0. In the dose-expansion portion, participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab will be administered at a dose of 200mg (3mg/kg for participants whose weight is below 50kg) IV on Day 1 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapeutic drug, ADC or PARP inhibitor
Description: Another anti-tumor drug chosen from chemotherapeutic drug, ADC, or PARP inhibitor will be administered at investigator's discretion.
Study: NCT04437563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HERMES
Description: Via an app, the caregiver answers 14 questions about his/her need for (more) information. The caregiver presents his/her answers (i.e., need for information) to the health care professionals (HCPs), and the HCPs provide the caregiver with the lacking information.
Study: NCT06363045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIDEK TONOREF III
Description: The auto ref/kerato/tono/pachymeter TONOREF III is a medical device which measures objective refractive errors, corneal curvature radius, intraocular pressure and corneal thickness of the patient's eye.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haag-Streit, PERKINS HAND-HELD APPLANATION TONOMETER
Description: Haag-Streit Goldmann Manual Tonometer measures intraocular pressure to aid in the screening and diagnosis of glaucoma

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIDEK CEM-530
Description: Nidek CEM-530 is a non-contact ophthalmic microscope, optical pachymeter, and camera used for examination of the corneal endothelium and for measurement of the thickness of the cornea.
Study: NCT04861480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-4-29 Cells
Description: Drug: C-4-29 Cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
Study: NCT04719338

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: presence of HCV RNA in peripheral blood mononuclear cells (PBMCs) .
Description: samples of peripheral blood from each patient into EDTA tube will be collected and tested for HCV RNA in peripheral blood mononuclear cells (PBMCs) .
Study: NCT06502470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ellacor® Micro-Coring procedure
Description: ellacor® Micro-Coring Technology is FDA approved for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV.
Study: NCT05401357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test - Bimatoprost 0.01% Ophthalmic Solution
Description: Subjects in one arm will receive one drop of the test drug in both the eyes every evening at approximately 10:00 pm ± 1 hour for 42 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
Description: Subjects in the other arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm for 42 days.
Study: NCT05642468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritivixibat
Description: 10mg tablet A3907 administered orally
Study: NCT06002607

Intervention type: OTHER
Intervention: Antibiotic duration
Description: The patient will be enrolled in a 48-hour course of antibiotics.

Intervention type: OTHER
Intervention: Antibiotic duration
Description: The patient will be enrolled in a 7 day course of antibiotics.
Study: NCT05987293

Intervention type: DEVICE
Intervention: Tracheal tube-tongue pressure is measured using a computerized occlusal analysis system based on T-Scan® technique, suitable for multi-point real-time monitoring of intraoral pressure.
Description: A flexible film sensor with a thickness of 0.11mm is placed between the tongue and the tracheal tube to measure the distribution, join force and dynamic changes of pressure at different site of the tongue. Five channels of pressure values will be recorded separately: (Ch1) the tip of the tongue, (Ch2) the middle of the tongue, (Ch3) the base of the tongue, (Ch4) the right side at the base of the tongue, (Ch5) the left side at the base of the tongue. The pressure values at the following points during the operation will be recorded: (t1) after intubation, (t2) highest pressure during patient positioning, (t3) after position fixed, (t4) at the end of surgery, (t5) before extubation.

Intervention type: DEVICE
Intervention: Tracheal tube-tongue pressure is measured using a computerized occlusal analysis system based on T-Scan® technique, suitable for multi-point real-time monitoring of intraoral pressure.
Description: A flexible film sensor with a thickness of 0.11mm is placed between the tongue and the tracheal tube to measure the distribution, join force and dynamic changes of pressure at different site of the tongue. Five channels of pressure values will be recorded separately: (Ch1) the tip of the tongue, (Ch2) the middle of the tongue, (Ch3) the base of the tongue, (Ch4) the right side at the base of the tongue, (Ch5) the left side at the base of the tongue. The pressure values at the following points during the operation will be recorded: (t1) after intubation, (t2) highest pressure during patient positioning, (t3) after position fixed, (t4) at the end of surgery, (t5) before extubation.
Study: NCT05383521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinidazole 56
Description: Tinidazole , 2g， twice daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinidazole 42
Description: Tinidazole , 1g, three times daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
Study: NCT05274880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393
Description: PO, QD
Study: NCT04968119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in telehealth exercise sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Participate in telehealth exercise sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05642468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritivixibat
Description: 10mg tablet A3907 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritivixibat
Description: 10mg tablet A3907 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritivixibat
Description: 10mg tablet A3907 administered orally
Study: NCT06639425

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei LC19 supplementation
Description: Orally administered Lactobacillus paracasei LC19 strain product, in addition to lifestyle intervention. This product is a probiotic milk powder, and the Lactobacillus paracasei LC19 strain is capable of producing high levels of tryptophan-conjugated cholic acid (Trp-CA)( 25g/packet, 2 packets/day).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo probiotic milk powder
Description: Orally administered placebo probiotic milk powder, in addition to lifestyle intervention. The placebo probiotic strain also belongs to Lactobacillus paracasei species, but does not produce Trp-CA. These products have the same color, odor, appearance, and packaging (25g/packet, 2 packets/day).
Study: NCT06483282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: This product is an orally administered targeted therapy drug, with a recommended dosage of one tablet per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 100mg/m2, administered every 3 Weeks (Q3W).
Study: NCT04968119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05424159

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy
Description: Patients with locally advanced unresectable pancreatic cancer without invasion of gastrointestinal tract will received ablative carbon ion radiotherapy. The prescription dose for primary pancreatic lesion, positive lymph node, and retroperitoneal high-risk recurrence area is 67.5 Gy (RBE weighted dose) in 15 fractions for 3 weeks; Pancreatic primary lesion and positive lymph node SIB to 75 Gy (RBE weighted dose) in 15 fractions for 3 weeks.
Study: NCT05100329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome injection
Description: 20 mg/m\^2, IV, on day 1 of every 3 weeks (q3w, a cycle)
Study: NCT04940676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Huzhangxiefei Decoction
Description: Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 10% Huzhangxiefei Decoction
Description: 10% Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
Study: NCT05043818

Intervention type: OTHER
Description: This study is an observational study and does not involve intervention.When the patient comes to the hospital or on the first to the second day of admission, the subject will be given a full scale check once（Screening related scales for anxiety and depression symptoms (PHQ9, SDS, HADS, HAMA, HAMD), inflammatory bowel disease quality of life scale (IBDQ), modified Mayo score for patients with ulcerative colitis/ simplified CDAI score for patients with Crohn's disease , Stool characteristics, degree of abdominal pain, gastrointestinal symptom scale (GSRS), etc.）. The stool sample will be collected once and 16S rRNA sequencing.

Intervention type: OTHER
Description: This study is an observational study and does not involve intervention.When the patient comes to the hospital or on the first to the second day of admission, the subject will be given a full scale check once（Screening related scales for anxiety and depression symptoms (PHQ9, SDS, HADS, HAMA, HAMD), inflammatory bowel disease quality of life scale (IBDQ), modified Mayo score for patients with ulcerative colitis/ simplified CDAI score for patients with Crohn's disease , Stool characteristics, degree of abdominal pain, gastrointestinal symptom scale (GSRS), etc.）. The stool sample will be collected once and 16S rRNA sequencing.
Study: NCT04586712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active CBD
Description: Participants will be provided a viscous liquid in a bottle with a syringe dropper containing CBD-extract oil at concentrations of 2000mg/30mL (high).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control (Placebo)
Description: Participants will be provided a viscous liquid in a bottle with a syringe dropper containing placebo containing no CBD oil (0mg/30 mL).
Study: NCT06317688

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra-Virgin Coconut Oil
Description: Active ingredients act as a destructor of bacteria, viruses and fungus
Study: NCT06453460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: Subjects will receive 14 weeks of letermovir prophylaxis at standard recommended dose follow by CMV-TCIP-directed extended prophylaxis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CMV T Cell Immunity Panel (CMV-TCIP)
Description: Viracor CMV-TCIP assay to measure how a person's immune system responds to CMV. Viracor CMV-TCIP will be measured monthly, starting at week 14, until positive, then at week 30 and 52.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CMV DNA PCR
Description: Plasma level of CMV DNA PCR will be measured at enrollment and at least weekly through week 30, then at least every 2 weeks through week 52 of transplant if no GVHD or CMV reactivation.
Study: NCT06516913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe Pump
Description: Used to administer buffer solution with hyaluronic acid SC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe Pump
Description: Used to administer buffer solution with hyaluronic acid SC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe Pump
Description: Used to administer buffer solution with hyaluronic acid SC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe Pump
Description: Used to administer buffer solution with hyaluronic acid SC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe Pump
Description: Used to administer buffer solution with hyaluronic acid SC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe Pump
Description: Used to administer buffer solution with hyaluronic acid SC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe Pump
Description: Used to administer buffer solution with hyaluronic acid SC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe Pump
Description: Used to administer buffer solution with hyaluronic acid SC
Study: NCT05468372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole 600 mg followed by posaconazole 300 mg once daily
Description: Posaconazole will be given as a delayed release tablet, the dose would be 600 mg in two divided doses on day 1, followed by 300 mg once a day from then on. If a subject vomits within 15 minutes of posaconazole tablet administration, the dosing should be repeated as soon as possible, following appropriate antiemetic treatment. The drug will be administered after a meal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Amphotericin B
Description: All study subjects will be administered intravenous liposomal amphotericin B \[5 mg/kg/day infusion in 5% dextrose solution\] over at least 2 hours, as per recommendations. Amphotericin B will be administered for the first seven days in the experimental arm, whereas it will be administered atleast for four weeks in the active comparator arm. Premedication or intravenous hydration will not be routinely administered. For patients experiencing chills, fever, hypotension, nausea, or other non-anaphylactic immediate infusion-related reactions, premedication (acetaminophen, diphenhyramine or hydrocortisone) will be administered 30 to 60 minutes prior to the next dose of amphotericin infusion.~The dose of intravenous amphotericin B will be modified further if required, based on the tolerability, and response to treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Amphotericin B
Description: All study subjects will be administered intravenous liposomal amphotericin B \[5 mg/kg/day infusion in 5% dextrose solution\] over at least 2 hours, as per recommendations. Amphotericin B will be administered for the first seven days in the experimental arm, whereas it will be administered atleast for four weeks in the active comparator arm. Premedication or intravenous hydration will not be routinely administered. For patients experiencing chills, fever, hypotension, nausea, or other non-anaphylactic immediate infusion-related reactions, premedication (acetaminophen, diphenhyramine or hydrocortisone) will be administered 30 to 60 minutes prior to the next dose of amphotericin infusion.~The dose of intravenous amphotericin B will be modified further if required, based on the tolerability, and response to treatment.
Study: NCT05866718

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Compassionate Touch Intervention
Description: Participants will be taught the micropractice (\<20-second/day personal practice) via video recording.
Study: NCT06483282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: This product is administered by intravenously guttae. AUC=5, administered every 3 Weeks (Q3W).
Study: NCT06644053

Intervention type: BEHAVIORAL
Intervention: Quantified analysis of walking during a crossing task through different horizontal openings
Description: Functional test that reproduce a task of daily living

Intervention type: BEHAVIORAL
Intervention: Quantified analysis of walking during a crossing task through different horizontal openings
Description: Functional test that reproduce a task of daily living
Study: NCT06643403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen 100% Gas for Inhalation
Description: SAUERSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~min. 95.5%, breathing for max. 45 minutes
Study: NCT04315883

Intervention type: BEHAVIORAL
Intervention: Quality of Life Assessment
Description: Evaluation of change of HRQOL survey responses will be performed:~* at baseline (time of treatment) and~* 1 month post treatment~* 6 months post treatment~* 12 months post treatment~* 5 years post-treatment~The HRQOL will be done by phone, mail or email. Responses will be captured and entered into a REDCAP database

Intervention type: RADIATION
Intervention: Transarterial Radioembolization
Description: Deliver catheter directed yttrium-90 directly to liver tumors and assess -Progression Free Survival - Local and Metastatic~* Local Tumor Response by calculating the decreases in tumor size and enhancement after treatment. This will be assessed by modified Response Evaluation Criteria for Solid Tumors (mRECIST).~* Resection Rate following treatment~* Transplant Rate following treatment~* Histologic Response by assessing tumor histopathology in patients who undergo tumor resection or liver transplant~* Biologic Response by monitoring serum tumor markers (e.g. alphafetoprotein-AFP) in AFP secreting tumors~* Review of clinical course post-treatment-rehospitalization rate
Study: NCT05919589

Intervention type: OTHER
Intervention: Care Integration for Children With Special Health Care Needs
Description: The Evelina London Children's Hospital (ELCH) is planning to integrate care for children with special health care needs (CSHCN) using a package of support, including 1) family support workers to manage care coordination and support parents, and 2) 'navigation' packs outlining key services, for both the services users and providers

Intervention type: OTHER
Intervention: Care Integration for Children With Special Health Care Needs
Description: The Evelina London Children's Hospital (ELCH) is planning to integrate care for children with special health care needs (CSHCN) using a package of support, including 1) family support workers to manage care coordination and support parents, and 2) 'navigation' packs outlining key services, for both the services users and providers
Study: NCT06474702

Intervention type: DEVICE
Intervention: 'Fitbit charge 4' 'smart-watch'-
Description: smartwatch device that collects physiological measures